NCT05514717 - A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung CancerHER2-positive Colorectal CancerHER2-positive TumorsHER2 Low Breast Cancer

Interventions

DRUG

XMT-2056

XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)

Trial Locations (14)

10016

RECRUITING

New York University Medical Oncology Associates, New York

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

30322

RECRUITING

Emory Healthcare, Emory Clinic, Atlanta

34747

RECRUITING

AdventHealth Celebration, Celebration

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

43212

RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

48201

RECRUITING

Karmanos Cancer Institute, Detroit

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

90033

RECRUITING

University of South California, Los Angeles

90095

RECRUITING

University of California Los Angeles, Los Angeles

94305

RECRUITING

Stanford University Medical Center, Stanford

02114

RECRUITING

Massachusetts General Hospital, Boston

07601

RECRUITING

Hackensack University Medical Center, Hackensack